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Antibacterial Activity of Ticagrelor in Conventional
Antiplatelet Dosages Against Antibiotic-Resistant
Gram-Positive Bacteria
Ticagrelor reversibly inhibits the platelet adenosine diphos-
phate P2Y12 receptor (P2Y12).1 It is approved for prevention of
cardiovascular events in patientswith atherosclerotic cardio-
vascular disease and shows evidence of superior clinical
performance compared with other P2Y12 inhibitors. A post
hoc analysis of the Comparison of Ticagrelor (AZD6140) and
Clopidogrel in Patients With Acute Coronary Syndrome
(PLATO) trial2 revealed thatpatients treatedwith ticagrelorhad
a lower risk of infection-related death than those treated
with clopidogrel bisulfate.3 More recently, in the Targeting
Platelet-Leukocyte Aggregates in Pneumonia With Ticagre-
lor (XANTHIPPE) study, ticagrelor was associated with im-
proved lung function inpatientshospitalized forpneumonia.4
We therefore questioned whether ticagrelor or its metabo-
lites could possess antimicrobial properties.
Methods | Ticagrelor and its major metabolites (M5
AR-C133913, M7, M8 AR-C124910)5 were synthetized and
tested in time-kill assays against gram-positive methicillin-
resistant Staphylococcus epidermidis RP62A (MRSE) (ATCC
35984); methicillin-sensitive Staphylococcus aureus (MSSA)
(ATCC 25904, ATCC 6538); glycopeptide intermediate
S aureus (GISA) Mu-50 (ATCC 700699); methicillin-resistant
S aureus (MRSA) (ATCC BAA-1556); Enterococcus faecalis
(ATCC 29212); vancomycin-resistant E faecalis (VRE) (ATCC
BAA-2365); and Streptococcus agalactiae (ATCC 12386) and
against gram-negative Escherichia coli (ATCC 8739) and
Pseudomonas aeruginosa (PAK laboratory strain). Biofilm for-
mation was assessed in vitro with crystal violet staining and
in a mouse model of S aureus polyurethane-implant infec-
tion using Xen-29 bacteria (Perkin Elmer). Infected disks
were implanted in specific pathogen-free BALB/cAnCrl mice
(Charles River). The mouse protocol was approved by the
ethical committee of Liège University.
Results | Ticagrelor and AR-C124910 had bactericidal activity
against all gram-positive strains tested, including drug-
resistant strains GISA, MRSE, MRSA, and VRE. The minimal
bactericidal concentration was 20 μg/mL against MSSA,
GISA, MRSA, and VRE; 30 μg/mL against MRSE; and 40
μg/mL against E faecalis and S agalactiae. Although a dosage
of 5 μg/mL delayed growth of MRSA, ticagrelor was ineffec-
tive against gram-negative strains in concentrations up to 80
μg/mL. At minimal bactericidal concentration, ticagrelor was
superior to vancomycin (Figure 1A), with rapid killing of late-
exponential-phase cultures of MRSA (time to kill 99.9% of
the initial inoculum, 2 hours). Bactericidal activity was simi-
lar to the bactericidal cyclic lipopeptide daptomycin,
recently introduced against resistant strains of S aureus
(Figure 1A). A subminimal bactericidal concentration of
ticagrelor (10 μg/mL) combined with vancomycin (4 μg/mL)
killed approximately 50% of the initial MRSA inoculum,
depicting synergistic activity. Ticagrelor also increased the
bactericidal activity of rifampicin, ciprofloxacin, and vanco-
mycin in a disk diffusion assay. It displayed bactericidal
activity against MRSE and VRE (Figure 1B and C), with supe-
riority over vancomycin for killing MRSE. At 24 hours, its
ability to kill MRSE and VRE was similar to daptomycin
(Figure 1B and C). Ticagrelor inhibited MRSA, MRSE, and
VRE biofilm formation in a dose-dependent manner
(Figure 1D-F); biofilm mass was reduced by more than 85%
after exposure to 20 μg/mL ticagrelor. Finally, in mice, con-
ventional oral antiplatelet dosages of ticagrelor (3 mg/kg
loading dose, then 1.5 mg/kg twice daily) inhibited biofilm
growth on S aureus–preinfected implants and dissemination
of bacteria to surrounding tissues (Figure 2).
Discussion | We describe bactericidal activity of ticagrelor
against antibiotic-resistant gram-positive bacteria that pose
a threat to human health. Although bactericidal concentra-
tions are not reached systemically in patients receiving typi-
cal dosages for treating cardiovascular disease (ticagrelor
Cmax = 1.2 μg/mL after one 180-mg loading dose and 0.75
μg/mL at 90 mg twice daily steady state), antibacterial activ-
ity at infection sites may still be achieved through local,
possibly platelet-driven, drug accumulation. Our findings
provide a mechanistic explanation for the reduced infection-
related death with ticagrelor seen in the PLATO trial3 and
could also explain improvement in lung function in patients
with pneumonia who took ticagrelor in the XANTHIPPE
study.4 These findings warrant further investigations,
including design of randomized clinical trials comparing the
protective activity of ticagrelor against gram-positive bacte-
rial infection in patients with cardiovascular disease with
other antiplatelet drugs. We are unaware of similar findings
with other P2Y12 inhibitors, and we did not observe in vitro
antibacterial activity of the active metabolite of prasugrel in
concentrations up to 100 μg/mL. Ticagrelor might prove
superior to other P2Y12 inhibitors in patients with cardiovas-
cular disease at risk for gram-positive bacterial infections
such as infective endocarditis.6 We did not isolate mutants
resistant to ticagrelor, and serial passaging of MSSA or MRSA
in the presence of subinhibitory concentrations of ticagrelor
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A-C Time-kill curves with ticagrelor (20 μg/mL for MRSA and VRE; 45 μg/mL for
MRSE), vancomycin (10 μg/mL), daptomycin (20 μg/mL for MRSA and VRE; 10
μg/mL for MRSE) or vehicle (1% DMSO). D-F. Mean biofilm biomass. Error bars
indicate SD. CFU indicates colony-forming units; DMSO, dimethylsulfoxide,
MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant
Staphylococcus epidermidis; and VRE, vancomycin-resistant Enterococcus
faecalis.
a P < .05.
bP < .01.
c P < .001.
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did not select for resistant mutants compared with ofloxacin
or rifampicin, which is reassuring for long-term antiplatelet
indications. There is a main limitation in this study that will
be addressed in future research. The in vivo demonstration
of antibacterial activity of ticagrelor antiplatelet dosages was
obtained in the mouse, which differs from humans in terms
of ticagrelor pharmacokinetics. Notwithstanding, our find-
ings also encourage future investigation of potential new
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A, Representative images of implantedmice before treatment and 24 hours
after treatment with ticagrelor or vehicle. B, Mean values of bioluminescent
signals. Error bars indicate SD. C, Skin sections (Gram stain [Sigma-Aldrich],
original magnification ×6.5). Blue areas represent bacteria. Bars = 50 μm.
p/s Indicates photon per signal.
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ticagrelor-derived antibiotics, devoid of antiplatelet activity,
against multiresistant staphylococci or enterococci.
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